Apollomics appoints Dr Jane Wang as CSO

China-based Apollomics Inc., with operating entities in California, an innovative biopharmaceutical company committed to the discovery and development of monoand combination- oncology therapies, has announced the appointment of Dr Jane Wang, as Chief Scientific Officer (CSO). In this role, Dr Jane will lead the drug discovery pipeline for the company. She will also serve as Apollomics’ China General Manager and will report to the Chief Executive Officer. Dr Jane brings over 20 years of drug discovery experience in the biopharmaceutical industry. Most recently, she served as Vice President, Medicinal Chemistry at WuXi AppTec where she worked to enhance RNA drug discovery and led multiple teams in medicinal chemistry and synthetic organic chemistry. Prior to WuXi, Dr Jane spent 12 years on the drug discovery team at Pfizer, Inc. as a senior principal scientist, focusing on diseases in oncology, inflammation, and the central nervous system. Previously, she did her postdoc in the U.S. National Institute of Health and at Schering-Plough.